T. Ohira

Efficacy and safety of pioglitazone added to alogliptin in Japanese patients with type 2 diabetes mellitus: a multicentre, randomized, double‐blind, parallel‐group, comparative study

K. Kaku, M. Katou, M. Igeta, 2015, Diabetes, obesity & metabolism.

Long‐term safety and efficacy of fasiglifam (TAK‐875), a G‐protein‐coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52‐week open‐label phase III study

K. Kaku, K. Enya, T. Ohira, 2016, Diabetes, obesity & metabolism.

Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience

P. Watkins, M. Munsaka, J. Marcinak, 2018, Drug Safety.

Effects of reduced food intake on toxicity study parameters in rats.

Hiroki Sugiura, T. Moriyama, Satoko Nonaka, 2008, The Journal of toxicological sciences.

Guidance on the need for contraception related to use of pharmaceuticals: the Japan Agency for Medical Research and Development Study Group for providing information on the proper use of pharmaceuticals in patients with reproductive potential

K. Kosaki, H. Negoro, Itsuko Horiguchi, 2022, International Journal of Clinical Oncology.

Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial

K. Kaku, K. Enya, T. Ohira, 2015, Diabetes, obesity & metabolism.

Efficacy and safety of pioglitazone added to alogliptin in Japanese patients with type 2 diabetes mellitus: a multicentre, randomized, double‐blind, parallel‐group, comparative study

K. Kaku, M. Katou, M. Igeta, 2015, Diabetes, obesity & metabolism.